옵션 체인은 다양한 행사가격과 만기일에 대한 Palomar Hldgs의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Palomar Hldgs에 대한 시장 심리를 평가합니다..

Palomar Hldgs (NASDAQ:PLMR) 주식, 옵션 체인

PALOMAR HOLDINGS INC

Palomar Hldgs

Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.

Palomar Holdings Inc

Evercore ISI Group analyst Michael Binetti maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $70.

News

Price Target

Analyst Ratings

BIRK

Evercore ISI Group Maintains Outperform on Birkenstock Holding, Raises Price Target to $70

Biotech

General

VNRX

VolitionRx Publishes  "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" In BMC Veterinary Research

Wells Fargo analyst Zachary Fadem maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Equal-Weight and lowers the price target from $85 to $75.

Wells Fargo Maintains Equal-Weight on Best Buy Co, Lowers Price Target to $75

Market-Moving Exclusives

Exclusives

GTBP

EXCLUSIVE: GT Biopharma Tells Benzinga 'The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts'

EXCLUSIVE: GT Biopharma Tells Benzinga 'Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2'

GT Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) announced Monday that it has successfully completed dosing in Cohort 1 and started dosing in Cohort 2 of its Phase 1 dose escalation trial for GTB-3650. The therapy is a second-generation TriKE therapeutic targeting relapsed or refractory CD33-expressing hematologic malignancies.
GT Biopharma specializes in immuno-oncology therapies using its proprietary TriKE NK cell engager platform and holds an exclusive global license with the University of Minnesota for its development and commercialization.
No safety or tolerability issues were observed in Cohort 1, allowing progression to the next cohort, the company said.
Early biomarker analysis from Cohort 1 patients indicates increased immunologic activity, suggesting activation and expansion of natural killer (NK) cells.
The trial, which may include up to 14 patients across seven cohorts, involves two-week dosing blocks over a four-month period and will evaluate safety, pharmacokinetics, pharmacodynamics, NK cell expansion, and clinical activity.
The company said that it will release detailed results in 2025.
In January, the company had initiated patient dosing with GTB-3650 in the Phase 1 trial to evaluate the potential in patients with hematological malignancies.
Price Action: GTBP stock traded higher by 0.90% to $2.26 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns" target="_blank" rel="noreferrer noopener">Moody's Downgrades U.S. Credit Rating Over Debt, Deficit Concerns</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Health Care

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

EXCLUSIVE: GT Biopharma Tells Benzinga Co. Advances GTB-3650 Phase I Trial To Cohort 2 Following Successful Initial Human Dosing And Evidence Of Early Immune Activation Signals

UHGWW

Trading Halt: Halt status updated at 8:30:00 AM ET: Quotation Resumption: News and Resumption Times

Wells Fargo analyst Zachary Fadem maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Overweight and raises the price target from $3850 to $4200.

Wells Fargo Maintains Overweight on AutoZone, Raises Price Target to $4200

Economist Peter Schiff has sharply criticized Treasury Secretary Scott Bessent for downplaying the role of President Donald Trump's tax cuts in the recent Moody's downgrade of the U.S. sovereign credit rating, instead pinning the blame on the Joe Biden administration.
What Happened: Schiff's comments, posted on X, come amid heated debates over the nation's fiscal health as the U.S. debt continues to spiral, now standing at a staggering $36.22 trillion.
In his post, Schiff highlighted that Moody's specifically cited the extension of Trump's 2017 tax cuts as a key reason for its decision to <a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns">downgrade the U.S. credit rating</a> from Aaa to Aa1 on May 16, 2025.
However, Bessent, in television interviews earlier on May 18, dismissed Moody's action as a "<a href="https://www.benzinga.com/markets/25/05/45484954/treasury-secretary-bessent-addresses-moodys-downgrade-and-tariff-impact-n-walmart">lagging indicator</a>," arguing that the downgrade reflected the Biden administration's spending policies rather than the tax cuts.
Bessent further claimed that the tax bill, which advanced through the House Budget Committee on May 18, would spur economic growth sufficient to outpace the nation's debt obligations. "I think that Moody's is a lagging indicator," Bessent said <a href="https://www.nbcnews.com/politics/trump-administration/scott-bessent-calls-moodys-lagging-indicator-us-credit-downgrade-rcna207535">on</a> NBC News' Meet the Press, adding, "That's what everyone thinks of credit agencies."
Schiff pushed back strongly against Bessent's narrative, accusing him of sidestepping the real issue.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Scott Bessent blamed the Moody&#39;s downgrade on the Biden administration. Yet Moody&#39;s specifically cited extending Trump&#39;s tax cuts as the reason for its decision. Bessent dismissed the downgrade as a lagging indicator. It&#39;s only lagging in that Moody&#39;s should have acted sooner.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1924412660730273973?ref_src=twsrc%5Etfw">May 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distorti">Trump&#8217;s Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight &#8216;Racket,&#8217; Pricing Distortion</a>
Why It Matters: The downgrade, which ended Moody's century-long pristine rating of the U.S. since 1919, was attributed to concerns over the nation's growing debt pile and the projected increase in fiscal deficits.
According to Moody's, the extension of these tax cuts—originally set to expire in 2025—would exacerbate the deficit, with nonpartisan analysts estimating an additional $3 trillion to $5 trillion added to the national debt over the next decade.
The agency also warned that the U.S. debt-to-GDP ratio could climb to 134% by 2035 if current trends persist.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.98% to $588.40, while the QQQ declined 1.40% to $514.19, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45465955/ark-invest-takes-swipe-at-mstr-mara-says-bitcoin-treasury-companies-dont-make-sense-fundin" target="_blank" rel="noreferrer noopener">Ark Invest Expert Takes Swipe At MSTR, MARA, Says ‘Bitcoin Treasury Companies Don't Make Sense:' ‘Funding Purchases With Debt…Seems Like A Recipe For Disaster'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

Markets

ETFs

Peter Schiff Slams Scott Bessent For Ignoring Trump's Tax Cuts In Moody's Downgrade, Blaming Biden Instead: 'It's Only Lagging In That Moody's Should Have Acted Sooner'

Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>), a global leader in comprehensive solutions for the hydrogen economy, today announced that its Chief Financial Officer, Paul Middleton, has purchased Plug's common stock in an open market transaction, underscoring his conviction in Plug's current strategy and future potential to dominate the hydrogen economy at scale. On May 16, 2025, Middleton acquired 350,000 shares at an average price of $0.7154 per share, for a total investment of approximately $250,000.

Insider Trades

PLUG

Plug Power CFO Paul Middleton Buys 350K Shares Of Stock At An Average Price Of $0.7154 Per Share, Or For ~$250,000 In Open Market Purchase

<h4 class="wp-block-heading">1. Event Overview: Strategic Leap Beyond Pilots</h4>
Pony AI&#8217;s (PONY) May 6th partnership with Uber (UBER) marks a paradigm shift for the autonomous vehicle (AV) unicorn: its Robotaxi fleet will integrate into Uber's global ride-hailing platform, starting in the Middle East H2 2025, with plans to expand to Europe and Asia. Unlike early-stage pilots, this collaboration is commercial-grade: Uber will handle fleet operations, while Pony provides its 7th-generation AV system—already deployed in 50 driverless taxis in Shenzhen and Abu Dhabi—enabling 100% mass production at 30% lower cost than legacy systems (company data).
<h4 class="wp-block-heading">2. Strategic Value: Scalability &gt; Geography</h4>
The Middle East's selection is shrewd:
<ul class="wp-block-list">
<li>Regulatory Friendliness: UAE/Dubai's "Autonomous Transportation Strategy 2030" targets 40,000 AVs by 2030, offering fast-track permits (Pony already operates 50 vehicles in Abu Dhabi).</li>
<li>High-Value Use Cases: Premium riders in GCC cities (median ride fare $15 vs. $8 in the U.S.) align with Pony's high-margin Robotaxi model ($0.5/km vs. human-driven $1.2/km).</li>
<li>Testbed for Global Expansion: Success here validates Pony's ability to operate in complex, multi-lingual environments ahead of EU entry (Luxembourg permit secured in April).</li>
</ul>
Uber's role is critical: its 122M monthly active riders and operational expertise reduce Pony's go-to-market costs by 40% (est.), compared to building standalone apps. This contrasts with rival Waymo, which relies on its own app in the U.S., limiting scalability.
<h4 class="wp-block-heading">3. Financial Catalysts: Revenue Diversification &amp; Margin Expansion</h4>
The partnership injects three revenue streams:
<ol start="1" class="wp-block-list">
<li>Ride-Sharing : 30-40% of Uber's ride revenue (est.), with Pony's cost per ride ($1.8) 65% lower than human drivers.</li>
<li>Vehicle Sales: Uber may purchase Pony's 7th-gen AVs, which achieve $250k/unit production cost (vs. $500k for L4 peers).</li>
<li>Data Monetization: Middle East operations generate 20% more complex urban scenarios than China, refining AI models for global licensing.</li>
</ol>
By 2026, we model this partnership contributing $210M in revenue (28% of total), lifting gross margin from 18% (2024) to 35% as scale reduces R&amp;D/support costs. Pony's Q1 2025 earnings (May 20) will likely reveal $45M in revenue (+120% YoY), driven by Shenzhen/Dubai operations.
<h4 class="wp-block-heading">4. Competitive Edge: Ecosystem vs. Technology</h4>
Pony differentiates via&nbsp;ecosystem lock-in:
<ul class="wp-block-list">
<li>Platform Partnerships: Uber, WeChat, DiDi, and Singapore's ComfortDelGro provide 60% of its user traffic, vs. 35% for Waymo.</li>
<li>Global Footprint: 8 cities in 4 regions (vs. Mobileye's 3), with 150+ vehicles deployed—largest non-U.S. fleet.</li>
<li>Regulatory Track Record: 12 commercial permits (incl. Shenzhen's first fully driverless license), vs. 5 for Argo AI (before shutdown).</li>
</ul>
The Uber deal also counters&nbsp;geopolitical risks: by focusing on non-U.S./China markets (60% of 2025 revenue target), Pony mitigates U.S. export limitation and China's data export restrictions.
<h4 class="wp-block-heading">5. Risks &amp; Valuation: Pricing the Execution</h4>
Key risks:
<ul class="wp-block-list">
<li>Localization Delays: UAE's insurance/liability frameworks for AVs remain immature.</li>
<li>Competition: Wenwenzhi (WRD.US) has 15-city Uber expansion plans, but lacks Pony's hardware integration (Wenwen relies on third-party cars).</li>
</ul>
Cash Burn: $120M Q1 2025 OCF (est.) requires $300M in 2025 funding, though partnerships reduce capital needs.

Travel

Opinion

Trading Ideas

Uber-Pony AI Partnership To Drive Robotaxi Leadership; Here's Why

Wells Fargo analyst Zachary Fadem maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Equal-Weight and lowers the price target from $40 to $35.

Wells Fargo Maintains Equal-Weight on Advance Auto Parts, Lowers Price Target to $35

ACADIA Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) announced a favorable <a href="https://www.benzinga.com/quote/ACAD">court ruling on Friday</a>.
The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia&#8217;s ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson's Disease Psychosis.
The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers.
&#8220;We are very pleased with today&#8217;s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,&#8221; said Catherine Owen Adams, Chief Executive Officer. &#8220;This result highlights Acadia&#8217;s dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs.&#8221;
ACADIA Pharmaceuticals shares gained 26.5% to close at $22.26 on Friday.
These analysts made changes to their price targets on ACADIA Pharmaceuticals following the announcement.
<ul class="wp-block-list">
<li>Needham analyst Ami Fadia maintained ACADIA Pharmaceuticals with a Buy and raised the price target from $27 to $30.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained the stock with a Buy and boosted the price target from $27 to $32.</li>
</ul>
Considering buying ACAD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="638" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-1024x638.png" alt="" class="wp-image-919746" style="width:687px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-1024x638.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-300x187.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-768x479.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230.png 1075w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ACAD

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.19) by 42.11 percent. This is a 87.78 percent increase over losses of $(0.90) per share from the same period last year. The company reported quarterly sales of $4.56 million which missed the analyst consensus estimate of $6.60 million by 30.84 percent. This is a 39.03 percent increase over sales of $3.28 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

EONR

Reported May 15, 2025: EON Resources Q1 EPS $(0.11) Beats $(0.19) Estimate, Sales $4.56M Miss $6.60M Estimate

&ndash; Capabilities across the InfoGenesis solution ecosystem equip Boyd Gaming&#39;s 28 properties with enhanced guest service capabilities &ndash;
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilysys.com%2Fen%2F&amp;esheet=54256500&amp;newsitemid=20250519073976&amp;lan=en-US&amp;anchor=Agilysys%2C+Inc.&amp;index=1&amp;md5=dc335f70ad4fe4011c6dce4cbb143c4f">Agilysys, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>), a leading global provider of hospitality software and services, today announced that Boyd Gaming Corporation has signed a Software-as-a-Service (SaaS) agreement for InfoGenesis, the Agilysys omnichannel enterprise POS ecosystem, to be deployed across its 28 gaming entertainment properties in the United States.
When fully implemented, data and transactions will be unified across all endpoints, including self-service kiosks, on-demand mobile food and beverage ordering profit centers and kitchen display stations. Data across systems will help Boyd optimize guest engagement and offers as well as operational decisions.
In addition to the InfoGenesis core system, Agilysys solutions in the agreement include OnDemand, guest self-service Kiosks, Kitchen Display Stations (KDS), Loyalty-Promotions and Analyze.

AGYS

Boyd Gaming Signs Software-As-A-Service Agreement With Agilysys For Infogenesis To Be Deployed Across Its 28 Gaming Entertainment Properties In US

<a href="https://www.globenewswire.com/Tracker?data=2KvvvJpv--9BC1F-UaczijKp0-qPU7WpfxTOfVNXqMLbDRV3KMtNZ9rG1Zpk5OuHFgVMqtrMOdGf9WJR5W7Iioa3D08FPMQ9S9mjuPLMh8g=">Blink Charging Co.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) ("Blink" or the "Company"), a leading global owner, operator, provider, and manufacturer of electric vehicle (EV) charging equipment and services, today announced a strategic restructuring plan designed to accelerate its BlinkForward objectives, enhance operational efficiencies, and position the Company for sustained long-term growth and profitability in the evolving global market.
The core of this plan includes a difficult but necessary reduction of the Company's global workforce by approximately 20%. This action is designed to streamline operations, enhance agility, and align resources with the Company's BlinkForward strategic priorities. These adjustments are anticipated to result in annualized savings of more than $11 million. The Company estimates it will incur between $1 million and $1.5 million of related costs, consisting of cash severance, other severance benefits, and other related restructuring costs. The workforce reduction is expected to be completed by the end of 3Q25.

Management

BLNK

Blink Charging Announces Strategic Restructuring Plan To Advance BlinkForward Goals, Improve Efficiency, And Drive Long-Term Growth, Including 20% Global Workforce Reduction Expected To Save Over $11M Annually Despite Up To $1.5M In One-Time Costs, With Completion Targeted By End Of Q3 2025

Chardan Capital analyst Geulah Livshits maintains Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) with a Buy and lowers the price target from $16 to $15.

SLDB

Chardan Capital Maintains Buy on Solid Biosciences, Lowers Price Target to $15

NVNO

enVVeno Medical Appoints Jennifer Bright As CFO

Press Releases

Palomar Holdings, Inc. Announces Third Quarter 2024 Financial Results Release Date and Conference Call

Palomar Holdings, Inc. Reports Third Quarter 2024 Results

Palomar Holdings, Inc. Appoints Benson Latham EVP, Head of Crop

Palomar Holdings, Inc. Completes Acquisition of First Indemnity of America Insurance Company

Palomar Holdings, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results Release Date and Conference Call

Palomar Holdings, Inc. Reports Fourth Quarter & Full Year 2024 Results

Palomar Holdings, Inc. to Host Investor Day

Palomar Holdings, Inc. Announces Agreement to Acquire Advanced AgProtection

Palomar Holdings, Inc. Announces First Quarter 2025 Financial Results Release Date  and Conference Call

Comments

Palomar Hldgs

Palomar Hldgs (PLMR) 옵션

Loading...

뉴스

파트너 / 기고자

벤징가 글로벌